☆ 4.7 Article

SARS-CoV-2 variants of concern partially escape humoral but not T- cell responses in COVID-19 convalescent donors and vaccinees

SCIENCE IMMUNOLOGY (2021)

Related references

Note: Only part of the references are listed.

Article Infectious Diseases

Genomic evidence for reinfection with SARS-CoV-2: a case study

Richard L. Tillett et al.

Summary: A man was infected with SARS-CoV-2 twice with genetically different virus variants, the second infection being more severe. The study suggests that previous exposure to SARS-CoV-2 may not guarantee immunity, and all individuals should take precautions to avoid infection. This has implications for vaccine development and application.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Adaptive immunity to SARS-CoV-2 and COVID-19

Alessandro Sette et al.

Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.

CELL (2021)

Add to Collection

Article Immunology

Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Recovery from Mild Coronavirus Disease 2019

Jee-Soo Lee et al.

Summary: The study found that recovered COVID-19 patients may be at risk of reinfection with a different strain of SARS-CoV-2, as the viral genome of reinfection differed from the initial infection. This suggests that SARS-CoV-2 infection may not provide immunity against other strains of SARS-CoV-2.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70, France, August to December 2020

Antonin Bal et al.

Summary: The study reported the strategy leading to the first detection of the variant of concern 202012/01 (VOC) in France, by screening for mutations such as Delta H69/Delta V70 associated with VOC and identifying co-occurring mutations like S:N501Y.

EUROSURVEILLANCE (2021)

Add to Collection

Review Microbiology

The Importance and Challenges of Identifying SARS-CoV-2 Reinfections

Ahmed Babiker et al.

Summary: Reports of SARS-CoV-2 reinfection have raised questions about the immune response and the possibility of partial immune protection. Further research is needed to elucidate the frequency, determinants, and consequences of these reinfections. Collaborative efforts involving clinical laboratories and investigators are crucial to establish frameworks for surveillance and investigation.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Evolution of antibody immunity to SARS-CoV-2

Christian Gaebler et al.

Summary: After infection with SARS-CoV-2, antibody levels against the spike protein decrease significantly, but the number of memory B cells remain unchanged, indicating an evolving humoral response at 6.2 months after infection.

NATURE (2021)

Add to Collection

Letter Medicine, General & Internal

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Alicia T. Widge et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity

Mads Delbo Larsen et al.

Summary: This study reveals that afucosylated IgG antibodies are specifically formed against enveloped viruses, but not generally against other antigens. These antibodies enhance Fc gamma RIIIa responses, but also exacerbate cytokine storms and immune-mediated pathologies.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Jeroen J. A. van Kampen et al.

Summary: The study found that the median duration of shedding infectious virus in COVID-19 patients is 8 days, dropping below 5% after 15.2 days post onset of symptoms. High viral loads are associated with infectious SARS-CoV-2 isolation, while high serum neutralizing antibody titres are associated with non-infectious SARS-CoV-2.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Wilfredo F. Garcia-Beltran et al.

Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou et al.

Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.

CELL (2021)

Add to Collection

Article Microbiology

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Xiaoying Shen et al.

Summary: Current COVID-19 vaccines target the ancestral SARS-CoV-2 spike, but the emerging B.1.1.7 variant with multiple spike mutations may impact some antibody therapies while posing no major concerns for vaccine efficacy or increased risk of reinfection.

CELL HOST & MICROBE (2021)

Add to Collection

Editorial Material Microbiology

The great escape? SARS-CoV-2 variants evading neutralizing responses

Jeremie Prevost et al.

Summary: The articles highlight the importance of surveillance of SARS-CoV-2 evolution to anticipate and manage new variants that could impact reinfection, vaccine efficacy, and immunotherapies.

CELL HOST & MICROBE (2021)

Add to Collection

Article Immunology

Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study

Gerco den Hartog et al.

Summary: The study found that specific IgG antibodies against SARS-CoV-2 persist in 92% of participants after 7 months, while IgM and IgA antibodies declined rapidly after the first month. Those with significant symptoms maintained more stable antibody concentrations and higher IgG binding strength compared to asymptomatic individuals or those with mild upper respiratory complaints.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Longitudinal Assessment of Antisevere Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019

Ji Yun Noh et al.

Summary: There is insufficient data on the longevity of immunity acquired after SARS-CoV-2 infection. The study found that most patients still carry neutralizing antibodies up to 6 months after diagnosis, which provides insights for establishing vaccination strategies against COVID-19.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

Ester C. Sabino et al.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Detection of a SARS-CoV-2 variant of concern in South Africa

Houriiyah Tegally et al.

Summary: The article describes a newly emerged lineage of SARS-CoV-2, 501Y.V2, characterized by eight mutations in the spike protein, which may result in increased transmissibility or immune escape. This lineage originated in South Africa and quickly became dominant in Eastern Cape, Western Cape, and KwaZuluNatal provinces within weeks.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

Add to Collection

Letter Biochemistry & Molecular Biology

COVID-19 vaccination: the VOICE for patients with cancer

Astrid A. M. van der Veldt et al.

NATURE MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Rita E. Chen et al.

Summary: The study analyzed antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants, showing significantly reduced neutralizing activity against the B.1.351 variant first identified in South Africa. Antibodies targeting the receptor-binding domain and N-terminal domain, monoclonal antibodies, convalescent sera, and mRNA vaccine-induced immune sera exhibited decreased inhibitory activity against viruses with an E484K spike mutation, suggesting a need for updated monoclonal antibodies or vaccine adjustments to prevent loss of protection against emerging variants.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Neutralizing Activity of BNT162b2-Elicited Serum

Yang Liu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma

For Yue Tso et al.

Summary: Specific IgG antibodies against SARS-CoV-2 were detected in all COVID-19 subjects, with most of them also showing high neutralizing potency and strong ADCC activity. These findings suggest that protection against SARS-CoV-2 may not only rely on neutralizing antibodies but also on ADCC mediated by both neutralizing and non-neutralizing antibodies.

PLOS ONE (2021)

Add to Collection

Article Psychology, Biological

A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker)

Thomas Hale et al.

Summary: The Oxford COVID-19 Government Response Tracker (OxCGRT) records data on 19 different government COVID-19 policy indicators for over 190 countries. Covering closure and containment, health and economics measures, it creates an evidence base for effective responses.

NATURE HUMAN BEHAVIOUR (2021)

Add to Collection

Article Immunology

SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8(+) T cell responses

Benedikt Agerer et al.

Summary: The study identified nonsynonymous mutations in MHC-I-restricted CD8(+) T cell epitopes of SARS-CoV-2 virus isolates, which resulted in diminished MHC-I binding of mutant peptides. This led to decreased proliferation, IFN-gamma production, and cytotoxic activity of CD8(+) T cells, along with qualitative differences in the transcriptional response to mutant peptides. These findings highlight the ability of SARS-CoV-2 to evade CD8(+) T cell surveillance through point mutations in MHC-I-restricted viral epitopes.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Prolonged evolution of the human B cell response to SARS-CoV-2 infection

Mrunal Sakharkar et al.

Summary: The study on the kinetics and evolution of the human B cell response to SARS-CoV-2 infection revealed that serum neutralizing antibody responses declined rapidly, while spike-specific IgG(+) memory B cells remained stable or increased over time. The research also showed evidence for prolonged antibody affinity maturation and the impact of mutations in the S protein on the neutralizing antibody response.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Markus Hoffmann et al.

Summary: The emerging SARS-CoV-2 variants may exhibit resistance to existing neutralizing antibodies and treatments, which could have significant implications for pandemic containment efforts.

CELL (2021)

Add to Collection

Article Microbiology

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Venkata Viswanadh Edara et al.

Summary: Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant.

CELL HOST & MICROBE (2021)

Add to Collection

Article Infectious Diseases

SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay

Irene Cassaniti et al.

Summary: The study evaluated the SARS-CoV-2 T-cell response in COVID-19 convalescent patients and unexposed individuals, showing that a majority of convalescent patients had a positive response to at least one SARS-CoV-2 antigen, which could last up to 12 months. The findings suggest that the SARS-CoV-2 T-cell response is primarily mediated by CD4 T cells.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Article Immunology

Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Chang Kyung Kang et al.

Summary: The memory T-cell response to SARS-CoV-2 persists for up to 8 months post-symptom onset, with potentially stronger responses in patients with severe illness compared to those with mild or asymptomatic disease. Further investigations are necessary to assess the longevity and protective effect of this immune response against reinfection.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Correlates of protection from SARS-CoV-2 infection

Florian Krammer

LANCET (2021)

Add to Collection

Letter Medicine, General & Internal

Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection

Salim S. Abdool Karim

LANCET (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Delphine Planas et al.

Summary: The ability of convalescent sera from individuals with coronavirus disease 2019 and those vaccinated with BNT162b2 to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351 decreases, but increases after two vaccine doses. The study found that the B.1.1.7 and B.1.351 variants may have acquired partial resistance to neutralizing antibodies generated by natural infection or vaccination, particularly in individuals with low antibody levels. This suggests that the B.1.351 variant may pose a greater risk of infection in immunized individuals.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

S. A. Madhi et al.

Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses

Ane Ogbe et al.

Summary: The study highlights the importance of distinguishing T cell responses to SARS-CoV-2 from cross-reactive immune responses to other coronaviruses, showing that the discriminatory ability is significantly influenced by the choice of antigens and type of assay used.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Critical Care Medicine

SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study

Andrew Letizia et al.

Summary: Young adults with SARS-CoV-2 antibodies have about one-fifth the risk of subsequent infection compared to those without antibodies. While antibodies from initial infection offer protection, they do not guarantee effective neutralization or immunity against future infection. These findings could impact mass vaccination strategies.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Immunology

Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals after mRNA vaccination

Rishi R. Goel et al.

Summary: mRNA vaccines exhibit robust serological and cellular priming, with naïve individuals requiring two doses for optimal antibody responses, especially against the B.1.351 variant. Memory B cells specific for spike protein and RBD were efficiently primed by vaccination, while recovered individuals showed significant boosting after the first dose, correlating with preexisting memory B cell levels. Identifying distinct responses based on prior SARS-CoV-2 exposure suggests that recovered subjects may only need one vaccine dose for peak responses, which can inform vaccine distribution strategies in resource-limited settings.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Letter Immunology

Confirmed Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant VOC-202012/01

David Harrington et al.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Cell Biology

Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies

Jeremy Dufloo et al.

Summary: Asymptomatic individuals infected with SARS-CoV-2 have lower levels of antibody response, but are still able to neutralize the virus and target infected cells. There are differences in antibody levels and functions between asymptomatic individuals and symptomatic cases, but antibody functions are correlated regardless of disease severity. Longitudinal samplings show that antibody functions follow similar kinetics of induction and contraction.

CELL REPORTS MEDICINE (2021)

Add to Collection

Article Cell Biology

Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection

Arunasingam Abayasingam et al.

Summary: The study suggests that while neutralizing antibodies in plasma may decline, the neutralizing capacity can still be maintained in the memory B cell repertoire. These memory B cells are capable of continuously producing antibodies with neutralizing capacity against SARS-CoV-2.

CELL REPORTS MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Chaolin Huang et al.

LANCET (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Alba Grifoni et al.

CELL (2020)

Add to Collection

Editorial Material Immunology

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

Meijuan Zheng et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2020)

Add to Collection

Article Immunology

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

Daniela Weiskopf et al.

SCIENCE IMMUNOLOGY (2020)

Add to Collection

Article Immunology

SARS-CoV-2 Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence

Gerco den Hartog et al.

JOURNAL OF INFECTIOUS DISEASES (2020)

Add to Collection

Article Oncology

The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study

Camille Maringe et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Julian Braun et al.

NATURE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Aaron J. Wilk et al.

NATURE MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Philip J. M. Brouwer et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Jose Mateus et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

Corine H. GeurtsvanKessel et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

Add to Collection

Article Medicine, Research & Experimental

High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19

David Schub et al.

JCI INSIGHT (2020)

Add to Collection

Article Medicine, Research & Experimental

Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals

Fang Gong et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Article Immunology

Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence

Gemma E. Hartley et al.

SCIENCE IMMUNOLOGY (2020)

Add to Collection

Article Immunology

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

Nisreen M. A. Okba et al.

EMERGING INFECTIOUS DISEASES (2020)

Add to Collection

Article Psychiatry

Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population

Matthias Pierce et al.

LANCET PSYCHIATRY (2020)

Add to Collection

Article Immunology

Severe SARS-CoV-2 patients develop a higher specific T-cell response

Julie Demaret et al.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2020)

Add to Collection

Article Immunology

Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity

Rory D. de Vries et al.

JOURNAL OF INFECTIOUS DISEASES (2018)

Add to Collection

Article Immunology

Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection

Rory D. de Vries et al.

VACCINE (2017)

Add to Collection

Article Multidisciplinary Sciences

Pre-fusion structure of a human coronavirus spike protein

Robert N. Kirchdoerfer et al.

NATURE (2016)

Add to Collection

Article Immunology

Age-Associated Cross-reactive Antibody-Dependent Cellular Cytotoxicity Toward 2009 Pandemic Influenza A Virus Subtype H1N1

Sinthujan Jegaskanda et al.

JOURNAL OF INFECTIOUS DISEASES (2013)

Add to Collection

Article Hematology

Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses

Pierre Bruhns et al.

BLOOD (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.